drugset
drugset / Trial / NCT02555618

Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants

NCT02555618 ↗

Phase 2 Completed 400 enrolled Takeda
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate the immunogenicity and safety of TAK-850 administered subcutaneously as a single dose versus influenza HA vaccination in an exploratory manner.

Timeline

Start
2015-09
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Influenza HA vaccine Vaccine 0.5 ml Subcutaneous
Subject TAK-850 Vaccine 0.5 ml Subcutaneous

Indications

influenza